Impaired DNA repair and genomic stability in hereditary tyrosinemia type 1

被引:5
|
作者
van Dyk, E. [1 ]
Pretorius, P. J. [1 ]
机构
[1] North West Univ, Ctr Human Metabon, Sch Phys & Chem Sci, ZA-2520 Potchefstroom, South Africa
基金
新加坡国家研究基金会;
关键词
Hereditary tyrosinemia; Microsatellite instability; Gene expression; Genetic instability; Hepatocellular carcinoma; MESSENGER-RNA LEVELS; MICROSATELLITE INSTABILITY; EXCISION-REPAIR; MURINE MODEL; FUMARYLACETOACETATE; CANCER; LIVER; EXPRESSION; DAMAGE; STRESS;
D O I
10.1016/j.gene.2011.12.021
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The autosomal recessive disorder, hereditary tyrosinemia type 1 (HT1), is caused by a defective fumarylacetoacetate hydrolase enzyme. Consequently intermediate metabolites such as fumarylacetoacetate, succinylacetone and p-hydroxyphenylpyruvic acid accumulate. Characteristic to HT1 is the development of hepatocellular carcinoma, irrespective of dietary intervention or pharmacological treatment. Carcinogenesis may occur through a chromosomal instability mutator phenotype or a microsatellite instability phenotype, and deficient DNA repair may be a contributing factor thereof. The purpose of this study was to investigate the expression of DNA repair proteins, and the possible occurrence of microsatellite instability in HT1. Gene expression analyses show low expression of hOGG1 and ERCC1 in HT1 patient lymphocytes. Results from microsatellite instability analyses show allelic imbalance on chromosome 7 of the fah(-/-) mouse genome, and instability of the 025123, D5S346 and (possibly) D17S250 microsatellite markers, in HT1 patient lymphocytes. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:56 / 61
页数:6
相关论文
共 50 条
  • [21] Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1
    Langlois, Chantale
    Jorquera, Rossana
    Finegold, Milton
    Shroads, Albert L.
    Stacpoole, Peter W.
    Tanguay, Robert M.
    BIOCHEMICAL PHARMACOLOGY, 2006, 71 (11) : 1648 - 1661
  • [22] siRNA Treatment for Hereditary Tyrosinemia Type I (HT1)
    Barzi, Mercedes
    Chen, Tong
    Hemmingsen, Madeline
    He, Gordon
    Keibler, Mark
    Sichani, Azadeh
    Garfinkel, Benny
    Bissig, Karl-Dimiter
    MOLECULAR THERAPY, 2023, 31 (04) : 284 - 284
  • [23] Imaging features of type 1 hereditary tyrosinemia: A review of 30 patients
    Dubois, J
    Garel, L
    Patriquin, H
    Paradis, K
    Forget, S
    Filiatrault, D
    Grignon, A
    Russo, P
    StVil, D
    PEDIATRIC RADIOLOGY, 1996, 26 (12) : 845 - 851
  • [24] Hereditary Tyrosinemia Type-1 With Late Presentation: A Case Report
    Ilyaz, Md
    Jadhav, Renuka S.
    Pande, Vineeta
    Mane, Shailaja
    Mokkarala, Pranavi
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (06)
  • [25] Early Phenotype Characterization of a Porcine Model of Hereditary Tyrosinemia Type 1
    Glorioso, Jaime
    Mao, Shennen A.
    Hickey, Raymond D.
    Lillegard, Joseph
    Fisher, James E.
    Finegold, Milton
    Marler, Ronald J.
    Grompe, Markus
    Nyberg, Scott L.
    HEPATOLOGY, 2013, 58 : 812A - 813A
  • [26] SINGLE DOSE NTBC-TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1
    Schlune, A.
    Thimm, E.
    Herebian, D.
    Spiekerkoetter, U.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2011, 34 : S81 - S81
  • [27] HEREDITARY TYROSINEMIA TYPE-I - AN OVERVIEW
    KVITTINGEN, EA
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1986, 46 : 27 - 34
  • [28] Clinical Spectrum of Hereditary Tyrosinemia Type 1 in a Cohort of Pakistani Children
    Khan, Sabeen Abid
    Fakih, Misbah
    Taufiq, Nida
    Ahmerin, Afaaf
    Bangash, Asfand
    Malik, Munir Iqbal
    CLINICAL MEDICINE INSIGHTS-PEDIATRICS, 2024, 18
  • [29] Consequences of a deficit of the tyrosine catabolism pathway: Hereditary tyrosinemia type 1
    Bergeron, A
    Jorquera, R
    Tanguay, RM
    M S-MEDECINE SCIENCES, 2003, 19 (10): : 976 - 980
  • [30] Nitisinone for the treatment of hereditary tyrosinemia type I
    McKiernan, Patrick James
    EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (06): : 491 - 497